RecruitingPhase 2

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

United States30 participantsStarted 2022-01-07

Plain-language summary

The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. absolute neutrophil count \>1,500/mcL
✓. platelets \>100,000/mcL
✓. total bilirubin ≤ 1.5 mg/dL
✓. creatinine ≤ 1.5 mg/dL
✓. AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal

What they're measuring

To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

Timeframe: through study completion, an average of 6 years (patients will be followed for 6 years after treatment completion

Trial details

NCT IDNCT05123807

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-02-02

Contact for this trial

Aaron Shafer, MD

832-885-6133 AShafer@mdanderson.org

View on ClinicalTrials.gov More Ovarian Cancer trials